Redwood City, CA, United States of America

James Joseph Cregg

This inventor holds 23 USPTO granted patents and 28 published patent applications and 6 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Revolution Medicines, Inc., Counsyl, Inc., University of California. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James Joseph Cregg. Retrieved from https://idiyas.com/inventor/james-joseph-cregg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.2

ph-index = 5

Forward Citations = 62(Granted Patents)


Location History:

  • San Francisco, CA (US) (2016 - 2022)
  • Redwood City, CA (US) (2023)
  • Belmont, CA (US) (2021 - 2024)

Company Filing History:


Years Active: 2016-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Ras Inhibitors
mTOR Inhibitors
Allosteric SHP2 Inhibitors
Bicyclic Compounds
Heteroaryl Compounds
Polycyclic Compounds
C26-Linked Rapamycin
Pyridine Compounds
High-Throughput Processing
Stress Resistance
Analogs
Compounds
23 patents (USPTO):Explore Patents

Title: The Innovative Mind of James Joseph Cregg: Pioneering Cancer Treatments

Introduction: James Joseph Cregg, an accomplished inventor based in Redwood City, California, holds an impressive portfolio of 11 patents. His groundbreaking work primarily focuses on the development of innovative pharmaceutical solutions aimed at combating various types of cancers through advanced molecular mechanisms.

Latest Patents: Among his latest innovations, Cregg has made significant contributions in the field of oncology with two notable patents. The first is centered around Ras inhibitors, featuring macrocyclic compounds and their pharmaceutical compositions capable of inhibiting Ras proteins. This invention has potential applications in the treatment of cancers, showcasing his dedication to advancing cancer therapy. The second patent involves C26-linked rapamycin analogs as mTOR inhibitors. This disclosure presents new compounds and compositions that inhibit the mTOR pathway, providing methods for treating diseases mediated by mTOR and outlining the synthesis of these vital compounds.

Career Highlights: James Joseph Cregg’s career is marked by his role at Revolution Medicines, Inc., where he contributes to pioneering research and development efforts in the field of cancer treatment. His work there significantly impacts the pharmaceutical industry, as he leads innovative projects aimed at discovering and creating new therapeutic options for patients.

Collaborations: Throughout his career, Cregg has worked alongside talented professionals, including coworkers Elena S. Koltun and Adrian L. Gill. These collaborations enhance the innovative environment at Revolution Medicines, Inc., fostering a culture of shared ideas and collective progress towards transforming cancer treatment.

Conclusion: James Joseph Cregg exemplifies the spirit of innovation through his dedicated work as an inventor. With a strong focus on developing groundbreaking cancer therapies, his contributions to the field are paving the way for improved treatment options. As he continues to push the boundaries of scientific discovery, Cregg's innovative mindset and collaborative spirit will undoubtedly lead to further advancements in medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…